Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
Price : $35 *
At a glance
- Drugs Fampridine (Primary)
- Indications Transverse myelitis
- Focus Therapeutic Use
- Acronyms Re-Launch
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2018 Status changed from active, no longer recruiting to completed.
- 15 Aug 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.